CARM carismatx.com: Forward P/S Multiple

Corporate emblem and logo of Carisma Therapeutics Inc (CARM)

Carisma Therapeutics (CARM) adheres to environmental standards regarding biohazardous waste disposal. The forward P/S history on GURU.Markets captures these processes, where the 0.60 indicator expresses the state of the metric. This trend is driven by the uniqueness of the CAR-macrophage platform for combating tumors, although high production costs and uncertainty surrounding insurance reimbursements create significant financial risks for the issuer.

Carisma Therapeutics Inc - CARM Forward P/S Multiple (period 04/28/2023 - 10/25/2025)

Analytical breakdowns for Carisma Therapeutics

Comprehensive company analysis:CARM (Carisma Therapeutics Inc.)
Product sample of Carisma Therapeutics Inc.

The development of Carisma Therapeutics (CARM) relies on internal development cycles and the commercialization of innovative drugs, which minimizes dependence on macroeconomic factors. An analysis of the company's expected P/S ratio allows for an assessment of the balance between market demand and projected revenue, determining the reliability of the price trend regardless of volume; high volatility in this indicator signals a speculative nature of the valuation and increased risks of a short-term price correction.

Competitors of Carisma Therapeutics (CARM)

Forward P/S Multiple ARGX (argenx.com)|BioNTech Group (BNTX) - Market Cap to Future Revenue Ratio|ABIVAX - Forward P/S Multiple|ADMA - Forward P/S Multiple|Protagonist (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Immunovant Inc|Price-to-Projected Revenue Ratio Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Price-to-Projected Revenue Ratio CLDX (Celldex Therapeutics)|Price-to-Projected Revenue Ratio Aurinia Pharma AUPH|Forward Price to Sales BCRX|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics)|Pharvaris N.V. (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio AbCellera Biologics (ABCL)|TRML (Tourmaline Bio Inc) - Forward P/S Multiple|Market Cap to Projected Revenue PGEN (Intrexon)|Forward Price-to-Revenue Multiple PHAR (Pharming)|NKTR (Nektar) - Forward Price to Sales|Forward P/S Multiple UPB (upstreambio.com)|ZBIO (Zenas Biopharma Inc) - Future Price to Revenue|IMNM - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Gossamer Bio Inc GOSS|KALV: Forward P/S Multiple|Forward Price-to-Revenue Multiple Septerna Pharma|PVLA (Pieris Corp) - Forward P/S Multiple|Price-to-Projected Revenue Ratio SVRA|Forward P/S Multiple RIGL|Forward Price-to-Revenue Multiple AnaptysBio Corp ANAB|Astria Therapeutics Inc - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio enGene Holdings Inc. (ENGN)|RAPT Therapeutics Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aerovate Therapeutics, Inc.|ACRS (Aclaris Therapeutics) - Forward Price-to-Revenue Multiple|KYTX: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Tiziana Life Sciences|Cabaletta Bio, Inc (CABA) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple VTYX (Ventyx Biosciences)|Market Cap to Expected Sales Ratio theratech.com|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc.)|Forward P/S Multiple Eledon Pharmaceuticals Inc. ELDN|AGEN: Forward Price-to-Revenue Multiple|Forward Price to Sales CLYM (Climb Bio, Inc)|ZURA: Forward P/S Multiple|aTyr Pharma, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Adagene Inc.|IMA: Forward Price to Sales|Forward P/S Multiple STTK|Forward Price-to-Revenue Multiple Equillium Bio EQ|Price-to-Projected Revenue Ratio Connect Biopharma CNTB|IMUX - Forward Price-to-Revenue Multiple|ATRA - Price-to-Projected Revenue Ratio|InflaRx NV (IFRX) - Forward Price-to-Revenue Multiple|XFOR (X4 Pharmaceuticals Inc.) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Adicet Bio Inc. (ACET)|Price-to-Projected Revenue Ratio celularity.com|Forward Price-to-Revenue Multiple inmunebio.com (INMB)|Price-to-Projected Revenue Ratio Barinthus Biotherapeutics PLC (BRNS)|Market Cap to Expected Sales Ratio Kezar Life Sciences Inc.|SAB Biotherapeutics, Inc - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Akari Therapeutics, Plc (AKTX)|ENLV: Forward Price-to-Revenue Multiple|Forward Price to Sales QTTB (q32bio.com)|GeoVax Labs Inc (GOVX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Edesa|Price-to-Projected Revenue Ratio iBio, Inc.|XTLB: Forward Price to Sales|Price-to-Projected Revenue Ratio Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio aptevotherapeutics.com APVO|AIM - Forward Price-to-Revenue Multiple|Aditxt - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRI Bio Corporation GRI|xortx.com (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio reshapelifesciences.com (HIND)|Price-to-Projected Revenue Ratio Revelation Bio|Market Cap to Future Revenue Ratio Indaptus Therapeutics, Inc. INDP|Price-to-Projected Revenue Ratio BiondVax Pharmaceuticals (SCNI)|Forward Price-to-Revenue Multiple CalciMedica CALI|Price-to-Projected Revenue Ratio Affimed AFMD|ALLK - Forward Price-to-Revenue Multiple|HOOKIPA Pharma, Inc. - Forward P/S Multiple|Forward Price to Sales IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Corp (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward P/S Multiple thirdharmonicbio.com